← 홈

Antibody

712개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 712개
AntibodyHotEli LillyreleaseApproved

Cetuximab (Cetuximab)

Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 757상태 RECRUITING
AntibodyHotRochederuxtecan (Dato-DXd, Datro…Approved

trastuzumab (Herceptin)

Non Small Cell Lung Cancer; Colorectal Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#Antibody#Approved#인기#항체+5
효능 ORR 91.8%임상시험 676상태 RECRUITING
AntibodyCHotRocheDM1) and trastuzumab deruxt…Phase 3

Pertuzumab (Pertuzumab)

Colorectal Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 91.8%임상시험 204상태 DISCONTINUED
AntibodyAHotAstraZenecaderuxtecan 3Phase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#인기#항체+5
효능 ORR 84.6%임상시험 181상태 RECRUITING
AntibodyBHotMerckVedotin ± Pe…Phase 3

Pembrolizumab (Immunotherapy, Immunotherapy (Pembrolizumab))

Melanoma (Skin Cancer); Melanoma Stage IIIB-IV · Locally Advanced Esophageal Squamous Cel

#LocallyAdvancedEsophagealSquamou#Antibody#Phase3#인기#항체+5
효능 ORR 41.6%임상시험 155상태 RECRUITING
AntibodyAHotRochePhase 2

combination (Trastuzumab plus Pertuzumab, Trastuzumab plus Pertuzumab (combination))

Cancer; Tumors · Cancer

#Cancer#Antibody#Phase2#인기#항체+5
효능 ORR 88.6%임상시험 144상태 RECRUITING
AntibodyBHotBiologicRocheDM1 via butelase-1 with ABD…Phase 1

HERCEPTIN (MAB HER 2, MAB HER 2 (HERCEPTIN))

Breast Cancer · Breast Cancer

#BreastCancer#Antibody#Phase1#인기#항체+5
효능 ORR 91.2%임상시험 113상태 RECRUITING
AntibodyBHotMerck KGaAvedotin (EV) was the most c…Phase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#인기#항체+5
효능 ORR 74%임상시험 105상태 ACTIVE
AntibodyCHotXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#인기#항체+5
임상시험 101상태 RECRUITING
AntibodyCMerckPhase 2

pembrolizumab (Keytruda, KEYTRUDA(R, Pembrolizumab (KEYTRUDA(R)))

Metastatic HPV-16 Positive Squamous Cell Anal Cancer · Metastatic HPV-16 Positive Squamous Cell

#MetastaticHPV-16PositiveSquamous#Antibody#Phase2#인기#항체+3
효능 ORR 78.3%임상시험 99상태 DISCONTINUED
AntibodySRocheDM1 via butelase-1 with ABD…Phase 3

trastuzumab (Herceptin)

Breast Cancer · Healthy

#Healthy#Antibody#Phase3#인기#항체+5
효능 ORR 91.2%임상시험 97상태 ACTIVE
AntibodyCPENG YUANPhase 2

QL1706 (Iparomlimab and Tuvonralimab, Iparomlimab and Tuvonralimab (QL1706))

Platinum Resistant Ovarian Cancer; Platinum Refractory Epithelial Ovarian Cancer · Gastric Cancer (GC)

#GastricCancerGC#Antibody#Phase2#인기#항체+5
임상시험 97상태 RECRUITING
AntibodyCBeiGeneVedotin, Tislelizumab, and …Phase 2

Tislelizumab (Tislelizumab)

Locally Recurrent Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 37.1%임상시험 96상태 RECRUITING
AntibodyCJunshi Biosciencesvedotin (EV) in combination…Phase 3

Toripalimab (Toripalimab)

Metastatic Colorectal Cancer; Liver Metastases · Gastric Cancer

#GastricCancer#Antibody#Phase3#인기#항체+5
임상시험 93상태 RECRUITING
AntibodyARochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody)

Triple-Negative Breast Cancer · Colorectal Cancer

#ColorectalCancer#Antibody#Phase3#인기#항체+4
효능 ORR 76.7%임상시험 90상태 ACTIVE
AntibodyCEli Lilly and CompanyDeruxtecan]Phase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#인기#항체+5
효능 ORR 40%임상시험 86상태 RECRUITING
AntibodyCRegeneronPhase 2

Cemiplimab (Cemiplimab)

Breast Neoplasms; Breast Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 44%임상시험 84상태 RECRUITING
AntibodyARocheGovitecanPhase 3

carboplatin-etoposide (Atezolizumab + chemotherapy, Atezolizumab + chemotherapy (carboplatin-etoposide))

Extensive Stage Small Cell Lung Cancer · Extensive Stage Small Cell Lung Cancer

#ExtensiveStageSmallCellLungCance#Antibody#Phase3#인기#항체+5
효능 ORR 100%임상시험 83상태 RECRUITING
AntibodyAAmgenPhase 3

Panitumumab (Panitumumab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 83상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab & Ipilimumab)

Carcinoma, Renal Cell; Clear-cell Metastatic Renal Cell Carcinoma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 61.3%임상시험 70상태 ACTIVE

1 / 36 페이지

← 이전다음 →